title: VAD or VMBCP in multiple myeloma refractory to or relapsing after cyclophosphamide-prednisone therapy (protocol MY 85).
abstract: 263 patients (median age 65+/-10 years) with multiple myeloma were treated with cyclophosphamide-prednisone. Out of this cohort, 103 patients had progressive disease and were randomly assigned to either VAD (vincristine, doxorubicin, dexamethasone; 50 cases) or VMBCP (vincristine, BCNU, cyclophosphamide, melphalan and prednisone; 53 cases). There were no statistical differences between the two groups with the respect to clinical, biological and radiological parameters. There was no difference in survival between the VAD and VMBCP groups. The 4 months response rate was similar in the two groups (50% VAD, 56% VMBCP). With multivariate analysis for survival (Cox model), two factors had a statistically significant impact: Karnofsky index (> 60) and albuminaemia (< 34 g/l). With both Karnofsky index > 60 and albuminaemia > or = 34 g/l, the median survival was 29 months v 2 months with a Karnofsky index < or = 60 and albuminaemia < 34 g/l (P<0.05). In conclusion, VAD or VMBCP had similar activity for salvage treatment in MM refractory or relapsing to first-line treatment with cyclophosphamide-prednisone.
authors.affiliation: Médecine Interne, Hôpital St Joseph, Gilly, Belgium.
authors.forename: P
authors.initials: P
authors.lastname: Mineur
authors.forename: J F
authors.initials: JF
authors.lastname: Ménard
authors.forename: X
authors.initials: X
authors.lastname: Le Loët
authors.forename: J F
authors.initials: JF
authors.lastname: Bernard
authors.forename: B
authors.initials: B
authors.lastname: Grosbois
authors.forename: J P
authors.initials: JP
authors.lastname: Pollet
authors.forename: I
authors.initials: I
authors.lastname: Azais
authors.forename: J P
authors.initials: JP
authors.lastname: Laporte
authors.forename: C
authors.initials: C
authors.lastname: Doyen
authors.forename: A
authors.initials: A
authors.lastname: De Gramont
authors.forename: M
authors.initials: M
authors.lastname: Wetterwald
authors.forename: L
authors.initials: L
authors.lastname: Euller-Ziegler
authors.forename: A M
authors.initials: AM
authors.lastname: Peny
authors.forename: M
authors.initials: M
authors.lastname: Monconduit
authors.forename: J L
authors.initials: JL
authors.lastname: Michaux
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002330:Carmustine / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D016879:Salvage Therapy; D015996:Survival Rate; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D008558:Melphalan; D002330:Carmustine; D011241:Prednisone